Please assess the completion status of the following clinical trial:

Trial Title: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA.~* Subjects must have a minimum of three (3) evaluable, discrete lesions.~* Subjects must be willing to refrain from sunbathing for the duration of the study.~Exclusion Criteria:~* History of sun hypersensitivity and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions or radiation therapy within 30 days of enrolling.~* Pregnancy or mothers who are breast feeding.~* Males and females not willing to use effective contraception.~* Unhealed sunburn.~* Subjects receiving topical steroids or other topical treatments for CTCL within 2 weeks.~* Subjects receiving systemic steroids, nitrogen mustard, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment.~* Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1.~* Subjects taking other investigational drugs or drugs of abuse within 30 days of entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGX301 (Type: ACTIVE_COMPARATOR): Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.

Based on this trial design, predict the completion outcome and termination type (if applicable).